| Project/Area Number |
25462615
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMADA KYOSUKE 東京慈恵会医科大学, 医学部, 准教授 (30230452)
TAKAKURA SATOSHI 東京慈恵会医科大学, 医学部, 講師 (60256401)
OCHIAI KAZUNORI 東京慈恵会医科大学, 医学部, 教授 (20152514)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | IL-6/STAT3シグナル / IL-6受容体 / 卵巣明細胞腺癌 / 卵巣癌 / 明細胞腺癌 / １IL-6/STAT3シグナル |
|---|
| Outline of Final Research Achievements |
Clear cell carcinoma of the ovary (CCC) has unique clinical and molecular characteristics. Recently, CCC was characterized by upregulation of the IL-6/IL-6R-Stat3 signal. In this study, we aim to clarify whether IL-6/IL-6R mediated signal pathway could have clinical relations with CCC and to evaluate inhibitory effects of the pathway on CCC carcinogenesis. A total of 84 CCC cases were evaluated by the immunohistochemical analysis for IL-6R and we found that high IL-6R expression correlated with poor patient survival. We further investigated the effects of IL-6/IL-6R signal inhibition either by IL-6R siRNA or humanized anti-human IL-6R antibody in CCC. Inhibition of endogenous IL-6R in CCC did reduce cell invasion ability and restored their response to cytotoxic reagent. These data suggest that IL-6/IL-6R signal could act on CCC cells to enhance invasion and chemoresistance and, therefore, targeting IL-6/IL-6R mediated signaling pathway could be a promising therapeutic strategy for CCC.
|
